Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for reduced effectiveness.
Source: NLP:efgartigimod alfa
2 interactions on record
Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for reduced effectiveness.
Source: NLP:efgartigimod alfa
Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for reduced effectiveness.
Source: NLP:rozanolixizumab